Osteoporosis Treatment: Robust Effects on 4 Outcomes
An evidence synthesis on bisphosphonates, denosumab, and romosozumab across vertebral, nonvertebral, hip, and bone-density endpoints for internal medicine clinicians
One-Minute Takeaway on Osteoporosis Treatment
One-Minute Takeaway
- Osteoporosis treatment is anchored by oral and intravenous bisphosphonates, which reduce vertebral, nonvertebral, and hip fractures across replicated Phase 3 trials and remain first-line for most patients.
- Denosumab is a potent antiresorptive with sustained 10-year efficacy, but discontinuation produces rapid bone loss and rebound vertebral fractures unless followed by bisphosphonate therapy.
- Romosozumab is a dual-action anabolic-antiresorptive option for patients at very high fracture risk, with a boxed warning regarding cardiovascular safety based on the ARCH trial imbalance.
- Anabolic-then-antiresorptive sequencing (romosozumab or teriparatide followed by a bisphosphonate or denosumab) provides greater fracture risk reduction than antiresorptive monotherapy in very high-risk patients.
- Major evidence gaps include head-to-head fracture-outcome comparisons, optimal duration after drug holidays, and long-term safety of newer agents.
Why Osteoporosis Treatment Has Become More Nuanced
Osteoporosis is one of the most prevalent yet undertreated chronic diseases in internal medicine. Roughly half of postmenopausal women and one in five men over age 50 will sustain an osteoporosis-related fracture in their lifetime, with hip fracture carrying mortality approaching 20% within one year.
The therapeutic toolkit has expanded substantially. Oral and intravenous bisphosphonates remain foundational, but denosumab introduced new considerations around discontinuation, and romosozumab brought a dual-action anabolic-antiresorptive mechanism with its own cardiovascular safety profile. Sequencing decisions now matter clinically.
Modern osteoporosis treatment is also being reframed as a long-term, often lifelong management problem rather than a finite course of pharmacotherapy. Major guidelines from the AACE, the Endocrine Society, and the American College of Physicians have converged on risk-stratified pathways that favor potent therapy in very high-risk patients.
The clinical question this review addresses: how should internal medicine clinicians integrate bisphosphonate, denosumab, and romosozumab evidence into osteoporosis treatment decisions, including initiation, sequencing, drug holidays, and discontinuation planning?
What Evidence Was Reviewed
This synthesis draws on the pivotal Phase 3 fracture-outcomes trials of alendronate, risedronate, and zoledronic acid; the FREEDOM and FREEDOM Extension trials of denosumab; the FRAME, ARCH, and STRUCTURE trials of romosozumab; the FLEX and HORIZON-PFT extension data on drug holidays; the Cummings 2018 post-hoc analysis of vertebral fractures after denosumab discontinuation; and current guidelines from AACE, the Endocrine Society, and the American College of Physicians.
Studies were prioritized by design (RCT before observational), sample size, and outcome relevance. Where head-to-head data are limited, indirect comparisons across trials with similar populations were used, with explicit attention to differences in fracture risk profiles between cohorts.
| Study / Source | Design | n | Key Finding Relevant to Osteoporosis Treatment |
|---|---|---|---|
| FIT (Black 1996) | Phase 3 RCT, alendronate vs placebo | 2,027 | Alendronate reduced vertebral fractures by ~47%; reduced hip fractures by ~51% |
| HORIZON-PFT (Black 2007) | Phase 3 RCT, zoledronic acid vs placebo | 7,765 | IV zoledronic acid reduced vertebral fractures by 70% and hip fractures by 41% over 3 years |
| VERT (Harris 1999) | Phase 3 RCT, risedronate vs placebo | 2,458 | Risedronate reduced vertebral fractures by 41%; nonvertebral by 39% |
| FREEDOM (Cummings 2009) | Phase 3 RCT, denosumab vs placebo | 7,868 | Denosumab reduced vertebral fractures by 68%, hip by 40%, nonvertebral by 20% |
| FREEDOM Extension (Bone 2017) | Open-label extension, 10-year exposure | 4,550 | Sustained low fracture incidence with continued denosumab over 10 years |
| Cummings 2018 post-hoc analysis | FREEDOM/Extension post-hoc | 1,001 discontinuers | Rapid BMD loss and excess vertebral fractures after denosumab discontinuation |
| FRAME (Cosman 2016) | Phase 3 RCT, romosozumab vs placebo | 7,180 | Romosozumab reduced new vertebral fractures by 73% at 12 months |
| ARCH (Saag 2017) | Phase 3 RCT, romosozumab vs alendronate | 4,093 | Romosozumab followed by alendronate reduced fractures more than alendronate alone; CV imbalance noted |
| STRUCTURE (Langdahl 2017) | Phase 3 RCT, romosozumab vs teriparatide | 436 | Romosozumab produced greater hip BMD gains than teriparatide in prior bisphosphonate users |
| FLEX (Black 2006) | Extension RCT, alendronate continuation | 1,099 | 5 vs 10 years of alendronate: small differences in fracture; informs drug-holiday decisions |
| ACP 2023 Guideline (Qaseem 2023) | Society guideline | NR | Bisphosphonates first-line; sequential anabolic-antiresorptive for very high risk |
Key Findings on Osteoporosis Treatment
Bisphosphonates Across the Fracture Outcome Spectrum
FIT, HORIZON-PFT, and VERT collectively established that bisphosphonates reduce vertebral, nonvertebral, and hip fractures in postmenopausal women with osteoporosis. Effect sizes are substantial: roughly 40–70% relative reduction in vertebral fracture, 20–25% in nonvertebral fracture, and 30–50% in hip fracture across the three pivotal agents.
The class effect supports interchangeability for most patients, with selection driven by route, dosing frequency, tolerability, and adherence. Oral alendronate or risedronate are typical first-line choices. Annual intravenous zoledronic acid is preferred when oral bioavailability or adherence is concerning, or when esophageal disease precludes oral therapy.
Long-term safety has been characterized through extension trials. Atypical femoral fractures and osteonecrosis of the jaw are rare but real concerns at extended exposures (typically beyond 5 years for oral or 3 years for IV agents), informing the clinical practice of bisphosphonate drug holidays in selected patients.
Mechanism Note
Bisphosphonates incorporate into bone mineral and inhibit osteoclast function via the mevalonate pathway, producing potent and durable antiresorption. The drugs persist in bone for years, which is the basis for the drug-holiday concept — therapeutic effect lingers after dosing stops, unlike denosumab.
Denosumab and the Discontinuation Question
FREEDOM established denosumab’s potent fracture reduction profile (vertebral 68%, hip 40%, nonvertebral 20% over 3 years). The FREEDOM Extension demonstrated sustained efficacy with continued treatment for up to 10 years and a low cumulative incidence of atypical fractures or osteonecrosis.
The critical contemporary issue is discontinuation. Cummings 2018 demonstrated that stopping denosumab without follow-on therapy produces rapid bone-mineral-density loss returning to baseline within roughly 12 months and a marked excess of vertebral fractures, including multiple vertebral fractures. This effect is biologically distinct from the slow tapering observed when bisphosphonates are stopped.
Practical implication: denosumab should not be stopped abruptly. Transition to a bisphosphonate (typically zoledronic acid or oral alendronate) at the time of the missed denosumab dose preserves much of the BMD gain and prevents the rebound fracture risk. This sequencing must be planned proactively.
Drug holidays are typically considered after 5 years of oral bisphosphonate or 3 years of IV zoledronic acid in patients at lower fracture risk. The rationale is to balance accumulated fracture risk reduction against rare adverse events that increase with longer exposure.
The FLEX trial showed that 5 versus 10 years of alendronate produced small fracture-rate differences for most outcomes, supporting holiday consideration in lower-risk patients. The HORIZON-PFT extension provides similar guidance for zoledronic acid.
Drug holidays are not appropriate for very high-risk patients (recent fracture, hip T-score ≤ -2.5, multiple risk factors, or ongoing glucocorticoid exposure). For these patients, continued therapy or switching to an alternative agent is preferred.
Bone mineral density measurement by DXA at 1 to 2 years after initiation is reasonable to confirm response or identify suboptimal response. Stable or improving BMD is the typical expectation; substantial BMD loss should prompt evaluation for adherence, secondary causes, or alternative therapy.
Bone turnover markers (CTX, P1NP) can supplement DXA, particularly for assessing adherence with oral bisphosphonates and for confirming biologic response to denosumab or romosozumab. Routine annual BMD is no longer recommended for stable patients on stable therapy.
Vertebral fracture assessment (lateral spine imaging) should be considered at baseline and during long-term therapy, since vertebral fractures are often clinically silent but indicate very high fracture risk.
Teriparatide (recombinant PTH 1-34) and abaloparatide (a PTHrP analog) are anabolic agents that stimulate bone formation. Both reduce vertebral and nonvertebral fractures and are appropriate for patients at very high fracture risk. Treatment duration is limited to 24 months due to historical osteosarcoma concerns from rodent studies.
Sequencing matters here too: anabolic-then-antiresorptive (teriparatide followed by a bisphosphonate or denosumab) preserves and extends bone gains. The reverse sequence (antiresorptive then teriparatide) is generally less effective at increasing BMD.
Romosozumab provides similar anabolic stimulation with an additional antiresorptive component, condensed into a 12-month course. Choice between these anabolic agents depends on insurance, route preference, comorbidity profile, and CV risk for romosozumab.
Romosozumab: Anabolic Effect and Cardiovascular Safety Considerations
Romosozumab is a humanized monoclonal antibody against sclerostin that simultaneously increases bone formation and decreases bone resorption. FRAME demonstrated a 73% reduction in new vertebral fractures versus placebo at 12 months, with sustained benefit through year 2 after transition to denosumab.
ARCH compared romosozumab followed by alendronate against alendronate alone in postmenopausal women with prior fracture and demonstrated greater fracture reduction with the romosozumab-then-alendronate sequence. STRUCTURE showed that romosozumab produced greater hip BMD gains than teriparatide in patients transitioning from oral bisphosphonate.
A cardiovascular safety signal emerged in ARCH, with a numerical excess of major adverse cardiovascular events in the romosozumab arm during the first 12 months. This was not seen in FRAME against placebo. The drug carries an FDA boxed warning advising against use in patients with myocardial infarction or stroke within the prior year.
Clinical Pearl: Romosozumab is best reserved for patients at very high fracture risk who have not had recent cardiovascular events. The 12-month course is followed mandatorily by an antiresorptive (denosumab or bisphosphonate) to maintain bone gains, since BMD declines rapidly after romosozumab discontinuation without follow-on therapy.
Sequencing, Drug Holidays, and Treatment Duration
Modern osteoporosis treatment is increasingly framed around long-term sequencing rather than single-agent monotherapy. For very high-risk patients, anabolic-first strategies (romosozumab or teriparatide) followed by antiresorptive therapy produce greater fracture reduction than antiresorptive monotherapy.
For lower-risk patients, oral or IV bisphosphonates remain the preferred initial choice, with drug-holiday consideration after 3 to 5 years and reassessment of risk before resuming therapy. Denosumab is appropriate for patients intolerant of bisphosphonates or with renal impairment, with mandatory transition planning before discontinuation.
Treatment duration decisions hinge on fracture risk reassessment rather than fixed time points. Continued therapy is appropriate for patients with persistent very high risk; drug holidays are appropriate for patients whose risk has declined; and switching agents is appropriate for patients with inadequate response or accumulating adverse effects.
Quality & Consistency of Evidence
The osteoporosis treatment evidence base is anchored by multiple large Phase 3 RCTs with histologic and radiographic primary endpoints. Heterogeneity exists in head-to-head fracture outcome comparisons and in long-term safety characterization for newer agents.
What the Evidence Does Not Show
Specific Evidence Gaps
Several clinically important questions in osteoporosis treatment remain unresolved. The named gaps below should shape patient counseling and ongoing trial design rather than be subsumed into a generic call for “more research.”
- Head-to-head fracture-outcome comparisons. Most direct comparisons (ARCH, STRUCTURE) used surrogate endpoints; few trials have powered hard fracture outcomes between active comparators.
- Optimal drug-holiday timing. Current 3- to 5-year thresholds are guideline consensus rather than RCT-validated, and reinstatement criteria are similarly under-evidenced.
- Romosozumab cardiovascular risk magnitude. The ARCH imbalance has not been independently replicated; absolute risk and predictors remain uncertain.
- Treatment in men and in glucocorticoid-induced osteoporosis. Evidence is largely extrapolated from postmenopausal trials; some agents have specific data but most do not.
- Combination therapy. Whether antiresorptive plus anabolic combination outperforms sequential strategies is uncertain.
- Long-term safety of denosumab and romosozumab. Beyond 10 years for denosumab and beyond 24 months for romosozumab, safety data are limited.
Practical Implications for Osteoporosis Treatment
Based on the current evidence, the following considerations represent areas where data are sufficiently consistent to inform routine internal medicine workflows. They are framed as evidence-supported considerations, not directive recommendations.
Evidence supports oral or IV bisphosphonates as first-line for most adults with osteoporosis, including patients with moderate fracture risk and good renal function.
Evidence supports planning denosumab discontinuation with immediate transition to a bisphosphonate to prevent rapid BMD loss and rebound vertebral fractures.
Evidence supports romosozumab for patients at very high fracture risk without recent CV events, followed mandatorily by an antiresorptive after the 12-month course.
Evidence supports sequencing romosozumab or teriparatide before a bisphosphonate or denosumab in very high-risk patients for greater fracture risk reduction than monotherapy.
Two further considerations complete the practical framework. Drug holidays remain reasonable for lower-risk patients after 3 to 5 years of bisphosphonate therapy, with reassessment of fracture risk to guide reinstatement. Calcium and vitamin D supplementation, fall prevention, and weight-bearing exercise complement pharmacotherapy across all risk strata; pharmacotherapy alone, without these foundations, captures only part of the achievable benefit.
Evidence Grade & Bottom Line
Overall Evidence Grade: Strong (fracture reduction across drug classes) to Moderate (sequencing strategies, romosozumab CV safety, drug-holiday timing) — Phase 3 evidence for fracture reduction with all three drug classes is robust. Sequencing strategies and CV safety characterization are areas of moderate evidence; drug-holiday optimization remains under-evidenced.
Bottom Line
- Bisphosphonates remain the foundation of osteoporosis treatment for most patients, with replicated Phase 3 evidence across vertebral, nonvertebral, and hip fracture outcomes.
- Denosumab provides potent antiresorption with sustained 10-year efficacy, but discontinuation must be planned with immediate transition to a bisphosphonate.
- Romosozumab is appropriate for very high-risk patients without recent cardiovascular events and must be followed by an antiresorptive to maintain bone gains.
- Anabolic-then-antiresorptive sequencing produces greater fracture reduction than antiresorptive monotherapy in very high-risk patients.
- Head-to-head fracture-outcome trials, drug-holiday optimization, and long-term safety of newer agents remain key unresolved questions.
Article Information & References
Disclaimer
For Educational Purposes Only. This is an original evidence synthesis informed by the studies listed below. It does not replace clinical judgement. Drug dosages should be verified against current prescribing information.
References
- Black DM, Cummings SR, Karpf DB, et al. Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures. Lancet. 1996;348(9041):1535-1541. DOI: 10.1016/s0140-6736(96)07088-2
- Black DM, Delmas PD, Eastell R, et al. Once-yearly zoledronic acid for treatment of postmenopausal osteoporosis. N Engl J Med. 2007;356(18):1809-1822. DOI: 10.1056/NEJMoa067312
- Harris ST, Watts NB, Genant HK, et al. Effects of risedronate treatment on vertebral and nonvertebral fractures in women with postmenopausal osteoporosis: a randomized controlled trial (VERT). JAMA. 1999;282(14):1344-1352. DOI: 10.1001/jama.282.14.1344
- Cummings SR, San Martin J, McClung MR, et al. Denosumab for prevention of fractures in postmenopausal women with osteoporosis. N Engl J Med. 2009;361(8):756-765. DOI: 10.1056/NEJMoa0809493
- Bone HG, Wagman RB, Brandi ML, et al. 10 years of denosumab treatment in postmenopausal women with osteoporosis: results from the FREEDOM Extension. Lancet Diabetes Endocrinol. 2017;5(7):513-523. DOI: 10.1016/S2213-8587(17)30138-9
- Cummings SR, Ferrari S, Eastell R, et al. Vertebral Fractures After Discontinuation of Denosumab: A Post Hoc Analysis of the Randomized Placebo-Controlled FREEDOM Trial and Its Extension. J Bone Miner Res. 2018;33(2):190-198. DOI: 10.1002/jbmr.3337
- Cosman F, Crittenden DB, Adachi JD, et al. Romosozumab Treatment in Postmenopausal Women with Osteoporosis (FRAME). N Engl J Med. 2016;375(16):1532-1543. DOI: 10.1056/NEJMoa1607948
- Saag KG, Petersen J, Brandi ML, et al. Romosozumab or Alendronate for Fracture Prevention in Women with Osteoporosis (ARCH). N Engl J Med. 2017;377(15):1417-1427. DOI: 10.1056/NEJMoa1708322
- Langdahl BL, Libanati C, Crittenden DB, et al. Romosozumab versus teriparatide in postmenopausal women with osteoporosis transitioning from oral bisphosphonate therapy: a randomised, open-label, phase 3 trial (STRUCTURE). Lancet. 2017;390(10102):1585-1594. DOI: 10.1016/S0140-6736(17)31613-6
- Black DM, Schwartz AV, Ensrud KE, et al. Effects of continuing or stopping alendronate after 5 years of treatment: the FLEX trial. JAMA. 2006;296(24):2927-2938. DOI: 10.1001/jama.296.24.2927
- Eastell R, Rosen CJ, Black DM, et al. Pharmacological Management of Osteoporosis in Postmenopausal Women: An Endocrine Society Clinical Practice Guideline. J Clin Endocrinol Metab. 2019;104(5):1595-1622. DOI: 10.1210/jc.2019-00221
- Camacho PM, Petak SM, Binkley N, et al. American Association of Clinical Endocrinologists/American College of Endocrinology Clinical Practice Guidelines for the Diagnosis and Treatment of Postmenopausal Osteoporosis — 2020 Update. Endocr Pract. 2020;26(Suppl 1):1-46. DOI: 10.4158/GL-2020-0524SUPPL
- Qaseem A, Hicks LA, Etxeandia-Ikobaltzeta I, et al. Pharmacologic Treatment of Primary Osteoporosis or Low Bone Mass to Prevent Fractures in Adults: A Living Clinical Guideline From the American College of Physicians. Ann Intern Med. 2023;176(2):224-238. DOI: 10.7326/M22-1034
- Black DM, Reid IR, Boonen S, et al. The effect of 3 versus 6 years of zoledronic acid treatment of osteoporosis: a randomized extension to the HORIZON-Pivotal Fracture Trial. J Bone Miner Res. 2012;27(2):243-254. DOI: 10.1002/jbmr.1494